Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis.

Feng S. et al, (2024), Health Technol Assess, 28, 1 - 109

Relationship between HLA genetic variations, COVID-19 vaccine antibody response, and risk of breakthrough outcomes

PRIETO ALHAMBRA D. et al, (2024), Nature Communications

Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases.

Yap RXL. et al, (2024), Vaccines (Basel), 12

Evaluating the impact of the biofire filmarray in childhood meningitis: an Observational Cohort Study

Kadambari S. et al, (2024), Pediatric Infectious Disease Journal, 43, 345 - 349

HLA Alleles, COVID-19 Vaccine Antibody Response and Real-World Breakthrough Outcomes

Prieto-Alhambra D. et al, (2023)

Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data

Feng S. et al, (2023), eClinicalMedicine, 61

Number needed to vaccinate for COVID-19 booster doses: a valuable metric to inform vaccination strategies

Feng S. et al, (2023), The Lancet Regional Health - Americas, 23, 100548 - 100548

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.

Liu X. et al, (2023), J Infect, 87, 18 - 26

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].

Liu X. et al, (2023), The Journal of infection, 86, 540 - 541

Cost-effectiveness of fractional doses of COVID-19 vaccine boosters in India

Du Z. et al, (2023), Med

Immunogenicity and seroefficacy of pneumococcal conjugate vaccines – a systematic review and network meta-analysis

Feng S. et al, (2023)

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.

Mentzer AJ. et al, (2023), Nat Med, 29, 147 - 157

The impact of repeated vaccination on relative influenza vaccine effectiveness among vaccinated adults in the United Kingdom.

Lim WW. et al, (2022), Epidemiol Infect, 1 - 30

Group B Streptococcus (GBS) colonization is dynamic over time, whilst GBS capsular polysaccharides-specific antibody remains stable.

Haeusler IL. et al, (2022), Clin Exp Immunol, 209, 188 - 200

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.

Munro APS. et al, (2022), Lancet Infect Dis, 22, 1131 - 1141

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.

Li G. et al, (2022), Lancet, 399, 2212 - 2225

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

Liu X. et al, (2022), J Infect, 84, 795 - 813

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2.

Hermosilla E. et al, (2022), Nat Commun, 13

Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50.

Xie J. et al, (2022), Nat Commun, 13

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng S. et al, (2021), Nature Medicine

Load More

Include forthcoming?